Kwangdong Pharmaceutical광동제약
009290 · KOSPI · ₩009290 · 광동제약
₩6,310▼ ₩60 (0.94%)End-of-day · Oct 29, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 18.4% | 18.1% | 18.2% | 19.8% | 19.7% | 20.5% |
| Operating margin | 2.0% | 1.9% | 1.8% | 2.8% | 2.7% | 3.4% |
| Net margin | 1.3% | 1.3% | 2.5% | 2.4% | 1.7% | 1.8% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +2.9% | +1.1% | +8.3% | +5.8% | +7.0% | — |
| Operating income growth | +8.0% | +3.2% | −28.5% | +10.0% | −14.9% | — |
| Net income growth | +4.1% | −48.2% | +9.5% | +52.9% | +0.6% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | 3.4% | 3.4% | 7.2% | 7.0% | 4.8% | 4.8% |
| Return on assets | 1.7% | 1.7% | 3.7% | 3.9% | 2.9% | 2.9% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 85.9% | 85.5% | 89.3% | 83.3% | 70.4% | 67.6% |
| Net debt to equity | 17.9% | 11.0% | 20.0% | — | −10.1% | −8.8% |
| Current ratio | 134.1% | 136.5% | 155.9% | 145.7% | 171.3% | 180.6% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Kwangdong Pharmaceutical / 광동제약 / 009290 / KRX:009290
Source: KRX statistical information